Raymond James & Associates acquired a new stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,121 shares of the biotechnology company’s stock, valued at approximately $507,000.
Several other institutional investors have also added to or reduced their stakes in ONCE. Tocqueville Asset Management L.P. raised its stake in Spark Therapeutics by 2.7% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock valued at $3,412,000 after purchasing an additional 1,075 shares during the period. Renaissance Technologies LLC bought a new stake in Spark Therapeutics during the 2nd quarter valued at approximately $4,635,000. Federated Investors Inc. PA raised its stake in Spark Therapeutics by 1.8% during the 2nd quarter. Federated Investors Inc. PA now owns 1,524,102 shares of the biotechnology company’s stock valued at $126,135,000 after purchasing an additional 26,314 shares during the period. Credit Agricole S A bought a new stake in Spark Therapeutics during the 2nd quarter valued at approximately $814,000. Finally, FMR LLC raised its stake in Spark Therapeutics by 2.6% during the 2nd quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock valued at $458,206,000 after purchasing an additional 142,428 shares during the period.
ONCE has been the topic of several recent analyst reports. Cantor Fitzgerald set a $103.00 target price on Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, October 1st. Raymond James restated a “buy” rating on shares of Spark Therapeutics in a report on Friday, September 21st. Credit Suisse Group raised their price target on Spark Therapeutics from $75.00 to $98.00 and gave the company an “outperform” rating in a report on Monday, July 9th. Guggenheim assumed coverage on Spark Therapeutics in a report on Tuesday, October 9th. They set a “buy” rating and a $70.00 price target for the company. Finally, ValuEngine cut Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $70.10.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.34). The company had revenue of $25.19 million during the quarter, compared to analysts’ expectations of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%. On average, analysts anticipate that Spark Therapeutics Inc will post -1.44 earnings per share for the current fiscal year.
Spark Therapeutics Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Featured Article: Hedge Funds – How They Work For Investors
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.